OVX836 480µg
Sponsors
Osivax
Conditions
Influenza
Phase 2
Immunogenicity and Safety of the Concomitant Administration of OVX836 and Quadrivalent Influenza Vaccine in Healthy Volunteers.
CompletedNCT05284799
Start: 2022-05-09End: 2022-12-09Updated: 2024-10-31
Efficacy, Immunogenicity and Safety of OVX836 Influenza Vaccine 480μg
Active, not recruitingNCT05569239
Start: 2025-09-08End: 2026-05-29Target: 2850Updated: 2025-12-17
Immunogenicity and Safety of the Concomitant Administration of OVX836 Influenza Vaccine, Quadrivalent Inactivated Influenza Vaccines and Placebo in Healthy Subjects.
CompletedNCT05734040
Start: 2023-05-10End: 2024-01-15Updated: 2024-01-25